Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial - The Lancet

Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial  The Lancet

Comments

Popular posts from this blog

Oncology: The disease, dynamics & challenges of market research

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Lung Cancer Among People Who Never Smoked